Akebia Therapeutics (AKBA) Other Accumulated Expenses (2013 - 2020)

Akebia Therapeutics (AKBA) has 8 years of Other Accumulated Expenses data on file, last reported at $2.5 million in Q1 2020.

• On a quarterly basis, Other Accumulated Expenses rose 16.32% year-over-year to $2.5 million in Q1 2020; TTM through Mar 2020 was $2.5 million, a 16.32% increase from a year earlier, with the FY2019 full-year figure at $9.5 million, down 20.97% from the prior year.
• Other Accumulated Expenses for Q1 2020 stood at $2.5 million, down from $9.5 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for AKBA reached as high as $12.8 million in Q2 2019 and fell as low as $1.3 million in Q1 2016.
• Historically, Other Accumulated Expenses has averaged $4.2 million across 5 years, with a median of $2.4 million in 2017.
• Across the five-year window, Other Accumulated Expenses jumped 410.0% in 2018 and sank 54.31% in 2019, its largest moves.
• Year by year, Other Accumulated Expenses stood at $1.9 million in 2016, then gained by 21.74% to $2.4 million in 2017, then soared by 410.0% to $12.1 million in 2018, then declined by 20.97% to $9.5 million in 2019, then sank by 74.25% to $2.5 million in 2020.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $2.5 million in Q1 2020, $9.5 million in Q4 2019, and $2.7 million in Q3 2019.